Stockscreener 앱 받기
2.08
1.42%
-0.03
시간 외 거래:
2.14
0.06
+2.88%
전일 마감가:
$2.11
열려 있는:
$2.08
하루 거래량:
130.06K
Relative Volume:
0.22
시가총액:
$31.16M
수익:
$1.16M
순이익/손실:
$-12.02M
주가수익비율:
-2.0037
EPS:
-1.0381
순현금흐름:
$-10.16M
1주 성능:
+4.00%
1개월 성능:
-4.15%
6개월 성능:
-12.61%
1년 성능:
-27.90%
1일 변동 폭
$2.05
$2.15
1주일 범위
$1.95
$2.15
52주 변동 폭
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
명칭
Dare Bioscience Inc
전화
858-926-7655
주소
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.08 | 29.66M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
Dare Bioscience (DARE) Holds Near Support After Marginal DeclineSector ETF Flow - newsline.com
Daré Bioscience Shareholders Back Governance and Capital Plans - The Globe and Mail
Daré Bioscience (NASDAQ: DARE) OKs equity line and boosts incentive plan shares - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock option grant - Stock Titan
Director Susan L. Kelley receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant - Stock Titan
Director Gregory Matz receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike - Stock Titan
Dare Bioscience Inc Annual Shareholders Meeting Transcript - GuruFocus
Dare Bioscience Company Profile & Introduction - Moomoo
Daré Bioscience to launch vaginal probiotic product - Investing.com
Daré Bioscience to launch vaginal probiotic product By Investing.com - Investing.com South Africa
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules - The Manila Times
New vaginal probiotic aims to support comfort — with 30% launch discount - Stock Titan
DARE Stock Price, Quote & Chart | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill
Dare Bioscience (DARE) Dips 2.15%, Hovers Above Key Support at $2.17ETF NAV Deviation - newsline.com
Dare Bioscience (DARE) Edges Higher Amid Steady Support LevelsThematic ETF Flow - The Legal Advocate
Daré Bioscience reports interim phase 3 data for Ovaprene By Investing.com - Investing.com Nigeria
Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus
Daré Bioscience receives second $1M NIH funding tranche - Investing.com UK
Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times
Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, Its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Moomoo
Dare Bioscience Inc (DARE) Stock Price, Quote, News & History - Benzinga
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 - Investing.com
Dare Bioscience, Inc.Common Stock (NQ: DARE - The Chronicle-Journal
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - Sahm
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com Australia
Dare Bioscience (DARE) Launches Phase 2 Study for DARE-HPV Treat - GuruFocus
Daré Bioscience Completes Regulation A Investor Unit Offering - TipRanks
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience (NASDAQ: DARE) issues 50,000 preferred unit package - Stock Titan
Dare Bioscience Q3 2025 Earnings Preview - MSN
Daré Bioscience begins phase 2 trial for HPV treatment By Investing.com - Investing.com South Africa
Daré Bioscience initiates phase 2 study of Dare-HPV - marketscreener.com
Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv - TradingView
Daré Bioscience begins phase 2 trial for HPV treatment - Investing.com
Daré Bioscience Initiates Phase 2 Study for DARE-HPV, Potential First Pharmacologic Treatment for High-Risk HPV Infection - Quiver Quantitative
6M women get high-risk HPV yearly; new trial tests first potential drug - Stock Titan
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Q1 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Str - GuruFocus
Daré Bioscience Releases Q1 2026 Financial Results - AlphaStreet
Daré Bioscience (DARE) Reports Positive Developments and Financi - GuruFocus
Daré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in June - MSN
Dare Bioscience (DARE) Q1 2026: EPS -$0.20 vs -$0.27 est (beat); - GuruFocus
Dare Bioscience Inc (DARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):